Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to -$0.92.

  • Intellia Therapeutics' EPS (Basic) rose 3134.33% to -$0.92 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.26, marking a year-over-year increase of 2169.12%. This contributed to the annual value of -$4.92 for FY2024, which is 614.53% up from last year.
  • Latest data reveals that Intellia Therapeutics reported EPS (Basic) of -$0.92 as of Q3 2025, which was up 3134.33% from -$0.98 recorded in Q2 2025.
  • Over the past 5 years, Intellia Therapeutics' EPS (Basic) peaked at -$0.69 during Q1 2021, and registered a low of -$1.96 during Q1 2022.
  • In the last 5 years, Intellia Therapeutics' EPS (Basic) had a median value of -$1.27 in 2024 and averaged -$1.24.
  • As far as peak fluctuations go, Intellia Therapeutics' EPS (Basic) tumbled by 18405.8% in 2022, and later soared by 4030.61% in 2023.
  • Quarter analysis of 5 years shows Intellia Therapeutics' EPS (Basic) stood at -$1.13 in 2021, then dropped by 22.43% to -$1.38 in 2022, then fell by 4.02% to -$1.44 in 2023, then rose by 11.34% to -$1.27 in 2024, then increased by 27.72% to -$0.92 in 2025.
  • Its EPS (Basic) stands at -$0.92 for Q3 2025, versus -$0.98 for Q2 2025 and -$1.1 for Q1 2025.